Viatris is bucking the trend of major pharma players exiting the consumer health market by partially reversing its decision to divest its OTC business.
The Canonsburg, PA-based firm described OTC as “non core” in November 2022 as it put the business up for sale along with its women’s healthcare and active pharmaceutical ingredients operations